Effect of early treatment with ivermectin among patients with covid-19.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorReis, Gilmar-
Autor(es): dc.creatorSilva, Eduardo Augusto dos Santos Moreira-
Autor(es): dc.creatorSilva, Daniela Carla Medeiros-
Autor(es): dc.creatorThabane, Lehana-
Autor(es): dc.creatorMilagres, Aline Cruz-
Autor(es): dc.creatorFerreira, Thiago Santiago-
Autor(es): dc.creatorSantos, Castilho Vitor Quirino dos-
Autor(es): dc.creatorCampos, Vitoria H. S.-
Autor(es): dc.creatorNogueira, Ana Maria R-
Autor(es): dc.creatorAlmeida, Ana Paula Figueiredo Guimarães de-
Autor(es): dc.creatorCallegari, Eduardo Diniz-
Autor(es): dc.creatorFigueiredo Neto, Adhemar Dias de-
Autor(es): dc.creatorSavassi, Leonardo Cançado Monteiro-
Autor(es): dc.creatorSimplicio, Maria Izabel Campos-
Autor(es): dc.creatorRibeiro, Luciene Barra-
Autor(es): dc.creatorOliveira, Rosemary-
Autor(es): dc.creatorHarari, Ofir-
Autor(es): dc.creatorForrest, Jamie I.-
Autor(es): dc.creatorRuton, Hinda-
Autor(es): dc.creatorSprague, Sheila-
Autor(es): dc.creatorMckay, Paula-
Autor(es): dc.creatorGuo, Christina M.-
Autor(es): dc.creatorRowland-Yeo, Kanters-
Autor(es): dc.creatorGuyatt, Gordon Henry-
Autor(es): dc.creatorBoulware, David R.-
Autor(es): dc.creatorRayner, Craig R.-
Autor(es): dc.creatorMills, Edward Joseph-
Data de aceite: dc.date.accessioned2025-08-21T15:24:24Z-
Data de disponibilização: dc.date.available2025-08-21T15:24:24Z-
Data de envio: dc.date.issued2023-06-26-
Data de envio: dc.date.issued2023-06-26-
Data de envio: dc.date.issued2021-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/16802-
Fonte completa do material: dc.identifierhttps://www.nejm.org/doi/full/10.1056/nejmoa2115869-
Fonte completa do material: dc.identifierhttps://doi.org/10.1056/NEJMoa2115869-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1013549-
Descrição: dc.descriptionBACKGROUND The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus dis- ease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coro- navirus 2 (SARS-CoV-2), is unclear. METHODS We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for >6 hours) within 28 days after randomization. RESULTS A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Find- ings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events. CONCLUSIONS Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424.)-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Título: dc.titleEffect of early treatment with ivermectin among patients with covid-19.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.